Centre Hospitalier Universitaire (CHU) d'Angers in France is conducting a clinical trial of RP103 called "CYST-HD Multicentre study of treatment of Huntington’s Disease with cysteamine, a randomized, controlled, double-blind multicenter phase II-III trial vs placebo."
The trial, in collaboration with Raptor, commenced in October 2010. Clinical researchers at CHU d’Angers, with input from researchers at the Curie Institute, have designed a protocol to investigate this potential mechanism in HD patients, using BDNF as a biomarker of potential efficacy.
Raptor is providing the clinical trial materials for this Phase 2 study, which is sponsored by CHU d’ Angers and funded by a grant from the French government. Eight clinical sites in France are enrolling 96 patients in a placebo-controlled, 18-month trial, followed by an open-label trial with all placebo patients rolling onto RP103 and all non-placebo patients continuing on RP103 for up to another 18 months. The primary end point of the trial will be based upon the Unified Huntington’s Disease Rating Scale, or UHDRS.